RT Journal Article
SR Electronic
T1 <sup>177</sup>Lu-PSMA Radioligand Therapy for Prostate Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1196
OP 1200
DO 10.2967/jnumed.117.191023
VO 58
IS 8
A1 Fendler, Wolfgang P.
A1 Rahbar, Kambiz
A1 Herrmann, Ken
A1 Kratochwil, Clemens
A1 Eiber, Matthias
YR 2017
UL http://jnm.snmjournals.org/content/58/8/1196.abstract
AB 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. The current literature suggests that this therapy is well tolerated and effective. On the basis of clinical need and current evidence, the therapy is being implemented in a growing number of centers worldwide. Here, we review important aspects of 177Lu-PSMA RLT, including patient stratification, the therapy protocol, concomitant medication, and follow-up, to inform medical staff involved in the RLT and care of patients with metastatic castration-resistant prostate cancer.